Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Company | Nivolumab - (CheckMate 577) | Esophageal or gastroesophageal junction cancer (EC/GEJC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Nivolumab plus ipilimumab (NIVO+IPI) - (CheckMate 901) | Previously untreated unresectable or metastatic urothelial carcinoma (mUC) | Phase 3 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Zeposia (ozanimod) - (YELLOWSTONE) | Crohn's disease | Phase 3 | Data Released | Oral | Gastroenterology |
| Bristol-Myers Squibb Company | Bempegaldesleukin (NKTR-214) and OPDIVO (nivolumab) - (PIVOT-10) | Urothelial cancer | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BNT327-02 | 1-2L Metastatic Triple-negative breast cancer (TNBC) | Phase 2 | Data Released | Intravenous | Oncology |
| Bristol-Myers Squibb Company | BMS-986278 | Progressive pulmonary fibrosis (PPF) | Phase 2 | Data Released | Oral | Respiratory |
| Bristol-Myers Squibb Company | Sitravatinib and Opdivo (Nivolumab) - (MRTX-500) | Nonsquamous (NSQ) Non–Small-Cell Lung Cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
| Bristol-Myers Squibb Company | Sitravatinib and OPDIVO (nivolumab) | Urothelial Carcinoma (Bladder) | Phase 2 | Trial Completed | Intravenous | Oncology |
